[HTML][HTML] Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
AS Mansfield, Z Wei, AT Shaw, CH Lieu… - NPJ Precision …, 2022 - nature.com
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
AS Mansfield, Z Wei, R Mehra, AT Shaw… - NPJ Precision …, 2022 - europepmc.org
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
AS Mansfield, Z Wei, R Mehra, AT Shaw… - NPJ Precision …, 2022 - search.proquest.com
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
AS Mansfield, Z Wei, R Mehra, AT Shaw… - NPJ Precision …, 2022 - search.ebscohost.com
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
[HTML][HTML] Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
AS Mansfield, Z Wei, R Mehra, AT Shaw… - NPJ Precision …, 2022 - ncbi.nlm.nih.gov
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
AS Mansfield, Z Wei, R Mehra, AT Shaw, CH Lieu… - 2022 - jdc.jefferson.edu
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
AS Mansfield, Z Wei, R Mehra… - npj Precision …, 2022 - utsouthwestern.elsevierpure.com
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
AS Mansfield, Z Wei, R Mehra… - npj Precision …, 2022 - mayoclinic.elsevierpure.com
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
AS Mansfield, Z Wei, R Mehra, AT Shaw… - NPJ Precision …, 2022 - europepmc.org
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …
agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to …